Last year, GEN published a list of the top 25 biotech companies. So, who would make the list this year? Find out by checking out this updated list of 25 biotech companies ranked by their market capitalization for the latest quarter that they furnished figures on their numbers of outstanding shares.
Overall, the past year has been mostly very good to biotechs where market cap is concerned, the result of a stock market surge that has not only lifted prices well into double-digits for most of the companies on the list, but also finally jumpstarted the market for initial public offerings after several years of spinning its wheels.
Indeed, five of the companies saw their market cap more than double, as investors primarily rewarded companies that brought new drugs through trials and FDA review, to market: BioMarin Pharmaceutical, Isis Pharmaceuticals, Onxy Pharmaceuticals, Vertex Pharmaceuticals, and especially Gilead Sciences, which nearly tripled its market cap after spending recent months integrating Pharmasset and growing its strong HIV portfolio with approvals last year for the combination drug Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), as well as and the first drug indicated for preventing the AIDS virus, the combo treatment Truvada (emtricitabine and tenofovir disoproxil fumarate).
Only two of the top 25 companies on this list (Teva and Elan) saw their share prices decline, in each case following unique challenges that had many of the same biotech investors heading for the proverbial exits.